Phenylalanine
16 benefits mapped to clinical evidence across supplements.
Dose per serving from products
844 products in our catalogue print how much Phenylalanine a serving holds.
Most common: 500 mg to 1 g, 40% of 844 products.
| Dose per serving | Products |
|---|---|
| 50 mg or less | 42 |
| 50 mg to 100 mg | 51 |
| 100 mg to 250 mg | 106 |
| 250 mg to 500 mg | 116 |
| 500 mg to 1 g | 337 |
| 1 g to 2.5 g | 172 |
| over 2.5 g | 20 |
Dose per serving from research
27 study groups in 6 studies say how much Phenylalanine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 5 mg/kg to 10 mg/kg and 25 mg/kg to 50 mg/kg, 33% of 27 study groups each.
| Daily dose | Study groups |
|---|---|
| 5 mg/kg or less | 2 |
| 5 mg/kg to 10 mg/kg | 9 |
| 10 mg/kg to 25 mg/kg | 5 |
| 25 mg/kg to 50 mg/kg | 9 |
| 50 mg/kg to 100 mg/kg | 2 |
Commonly used together
19 of 44 study groups took Phenylalanine with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| L-Tyrosine | 13 |
| Essential Amino Acids | 4 |
Benefit Evidence
Low Phe/Tyr: less motivation/confidence
High Phe: worse motivation/confidence
Low Phe/Tyr: less motivation/confidence
High Phe: worse motivation/confidence
Research sources
Brain health (138)
- Bidirectional modulation of reward-guided decision making by dopamine
PubMed ID: 40439740
Pharmacological boosting of dopamine altered decision‑making attributes, consistent with brain chemistry modulation.
- The efficacy of levodopa/carbidopa/entacapone on cognitive function in moderate to advanced Parkinson's disease and its relationship with peripheral inflammatory cytokines
PubMed ID: 40108546
Entacapone added to levodopa improved MoCA scores and lowered IL‑6, with cognitive improvement correlating with biomarker changes.
- Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease
PubMed ID: 40736131
Large trials of continuous levodopa prodrug showing robust clinical effects, indirectly proving dopaminergic pathway modulation.
- Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial
PubMed ID: 40008823
Mesdopetam (D3 antagonist) produced dose-dependent effects on dyskinesia and motor endpoints — clearly modulates dopaminergic receptor signaling relevant to brain chemistry.
- Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial
PubMed ID: 41269916
Direct trial of Mucuna (natural L‑DOPA) vs levodopa/carbidopa showing comparable motor/non‑motor and QoL improvements — strong support that precursor provision alters brain catecholamine chemistry.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Tyrosine/phenylalanine-free dietary manipulation decreased dopamine neurotransmission and reduced psychostimulant and mania effects — direct evidence that precursor availability shapes brain chemistry (strong inverse evidence).
- Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients
PubMed ID: 12860366
IFN‑alpha raised PHE/TYR ratio and altered amino acid profiles — direct biochemical data on phenylalanine/tyrosine metabolism in humans.
- Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes
PubMed ID: 20008998
Demonstrated increase in putamen 18F-FDOPA uptake and clinical improvement — direct evidence of modifying brain dopaminergic chemistry (phenylalanine is upstream of tyrosine/dopamine).
- Dopamine Depletion Reduces Food-Related Reward Activity Independent of BMI
PubMed ID: 26450814
APTD blunted striatal fMRI reward responses and hippocampal interactions — directly shows Phe/Tyr precursor availability impacts brain reward circuitry.
- Dopamine depletion effects on cognitive flexibility as modulated by tDCS of the dlPFC
PubMed ID: 31494070
APTD slowed RTs and modulated cognitive flexibility with dlPFC tDCS interactions — supports role of Phe/Tyr in catecholaminergic brain function.
- Blue Monday: Co-occurring Stimulant Use and HIV Persistence Predict Dysregulated Catecholamine Synthesis
PubMed ID: 33165125
Direct measurement of P/T ratio (phenylalanine/tyrosine) as a biomarker of catecholamine precursor metabolism and its link to depression—highly relevant.
- Brain glucose uptake is associated with endogenous glucose production in obese patients before and after bariatric surgery and predicts metabolic outcome at follow-up
PubMed ID: 30098134
Circulating Phe associated with insulin-stimulated brain glucose uptake, linking Phe to brain metabolic/neurochemical context.
- Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept
PubMed ID: 22162828
Metabolomics showing a phenylalanine‑pathway biomarker predicts SSRI response—strongest dataset link here to central neurotransmitter biochemistry (associative).
- Randomized controlled trial of a protein substitute with prolonged release on the protein status of children with phenylketonuria
PubMed ID: 24724767
Direct clinical relevance: PKU management (phenylalanine restriction/ substitutes) is a principal way to protect brain chemistry by controlling Phe exposure.
- Relative Oral Bioavailability and Food Effects of Two Sepiapterin Formulations in Healthy Participants
PubMed ID: 38156759
Sepiapterin→BH4 PK study: BH4 is essential cofactor for phenylalanine hydroxylase and neurotransmitter synthesis (direct mechanistic relevance).
- Differential, but not opponent, effects of L -DOPA and citalopram on action learning with reward and punishment
PubMed ID: 24232442
Pharmacological manipulations produced robust computational changes in action/valence parameters—strong support for neurotransmitter mediation.
- The relationship between neurotransmission-related amino acid blood concentrations and neuropsychological performance following acute exercise
PubMed ID: 35227132
Exercise-induced rises in PHE/TYR correlated with cognitive test improvements, showing physiological modulation of neurotransmitter precursors.
- Elevated serum prolactin concentrations in phenylketonuric patients on a 'loose diet'
PubMed ID: 9509074
PKU patients with high Phe showed large increases in prolactin and decreases in dopamine—clear clinical/biochemical demonstration that Phe affects neurochemistry.
- A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone
PubMed ID: 24424425
Levodopa (dopamine precursor) effects in cocaine users provide indirect evidence about modulation of brain chemistry via monoamine precursors.
- The effects of combination levodopa-ropinirole on cognitive improvement and treatment outcome in individuals with cocaine use disorder: A bayesian mediation analysis
PubMed ID: 34102508
Dopamine-augmenting medication improved attention/impulsivity and clinical outcomes, supporting the role of dopamine synthesis pathways linked to Phe→Tyr.
- A randomized trial of long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria
PubMed ID: 16483397
PKU infant dietary management (Phe restriction) and its interaction with brain LC-PUFA status underscores the importance of Phe metabolism to neurodevelopment/chemistry.
- START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients
PubMed ID: 22112818
Randomized placebo-controlled sapropterin trial identifies genotypes responsive with substantial blood-Phe reductions — direct clinical evidence that interventions can modulate Phe available to the brain.
- Global testing of shifts in metabolic phenotype
PubMed ID: 30830386
Metabolomics finds Phe/Tyr pathways altered with obesity and changed by interventions — supports systemic modulation of aromatic-AA brain-precursor pathways.
- The effects of a branched chain amino acid mixture supplemented with tryptophan on biochemical indices of neurotransmitter function and decision-making
PubMed ID: 15696331
High BCAA mixture (with TRP) substantially lowered TYR+PHE:BCAA ratio and produced endocrine/cognitive changes — mechanistic evidence that PHE/TYR availability affects brain neurotransmission.
- Nutritional evaluation of children with phenylketonuria
PubMed ID: 10592130
PKU children on phenylalanine‑restricted diets had nutritional deficits and growth impacts—illustrates the clinical consequences of manipulating Phe for brain health.
- Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial
PubMed ID: 27413125
PKU clinical dietary trial showing AA vs GMP medical foods changed fasting plasma Phe substantially—direct relevance to brain Phe exposure and neurochemistry.
- Dopamine and light: effects on facial emotion recognition
PubMed ID: 28633582
Direct experimental manipulation of Phe/Tyr availability produced clear dopamine‑linked changes in emotion processing — strong evidence that Phe availability alters brain chemistry.
- Intellectual development in 12-year-old children treated for phenylketonuria
PubMed ID: 1985428
Clear clinical evidence linking lifetime Phe exposure with cognitive outcomes — demonstrates the central importance of Phe control to brain development/chemistry.
- Phenylketonuria in adulthood: a collaborative study
PubMed ID: 12408183
PKU long-term follow-up demonstrates how brain Phe levels influence neurological and behavioral outcomes; crucial evidence about Phe and brain chemistry.
- Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study
PubMed ID: 17693179
Sapropterin greatly lowers blood Phe in PKU—direct, high‑quality evidence of modifying Phe metabolism that affects brain chemistry.
- Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria
PubMed ID: 18932221
Sapropterin significantly lowered plasma phenylalanine in BH4-responsive PKU patients; demonstrates clinical importance of Phe regulation for brain‑relevant biochemistry in PKU.
- Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study
PubMed ID: 19261295
Sapropterin increased dietary Phe tolerance in PKU, directly relevant to managing Phe-related brain-chemistry exposure.
- Pre-attentive processing in children with early and continuously-treated PKU. Effects of concurrent Phe level and lifetime dietary control
PubMed ID: 21541727
Associations between blood Phe and evoked potentials in PKU children indicate Phe influences neurophysiology/brain chemistry.
- Acute phenylalanine/tyrosine depletion reduces motivation to smoke cigarettes across stages of addiction
PubMed ID: 21775977
APTD decreased motivation to work for nicotine, showing Phe/Tyr depletion affects dopamine-driven behavior—strong brain chemistry link.
- "MY PKU": increasing self-management in patients with phenylketonuria. A randomized controlled trial
PubMed ID: 21708003
Monitoring/management of blood Phe in PKU affects brain exposure to Phe and thus brain chemistry.
- Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients
PubMed ID: 21491106
Acute Phe loading and chronic PKU altered frontal‑executive performance and brain activation — direct human brain chemistry relevance.
- A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria
PubMed ID: 25533024
Sapropterin lowered blood Phe in PKU and improved attention/executive measures—direct evidence that Phe levels affect CNS function.
- Serotonin and dopamine differentially affect appetitive and aversive general Pavlovian-to-instrumental transfer
PubMed ID: 25034118
Dietary depletion of tyrosine/phenylalanine altered motivated behavior, directly showing behavioral effects of changing Phe/tyrosine availability.
- Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial
PubMed ID: 28274234
Sapropterin (BH4) restores Phe hydroxylation capacity in BH4‑responsive PKU, directly affecting Phe→Tyr conversion and brain chemistry.
- Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
PubMed ID: 29653686
Pegvaliase program shows that lowering pathological blood Phe in PKU produces sustained biochemical normalization and neuropsychiatric improvements—strong evidence that Phe levels shape brain chemistry and function.
- Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
PubMed ID: 30366815
Direct, substantial reductions in blood Phe with pegvaliase — central to brain Phe/Tyr balance and neurotransmitter synthesis in PKU.
- Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial
PubMed ID: 29628378
Switching off pegvaliase led to large Phe rises, underscoring the central role of Phe control in brain chemistry.
- Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers
PubMed ID: 30922814
Sepiapterin raises BH4, the cofactor for Phe hydroxylase, supporting enzymatic conversion central to brain neurotransmitter precursor balance.
- Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria
PubMed ID: 31296884
Nitisinone alters tyrosine/phenylalanine metabolic flux markedly, which is directly relevant to brain precursor availability.
- Effects of serotonin depletion and dopamine depletion on bimodal divided attention
PubMed ID: 30295116
Direct APTD/tyrosine manipulations in healthy adults show Phe/Tyr availability alters neurotransmitter‑related cognitive measures—strong mechanistic support that Phe affects brain chemistry.
- Preliminary evidence for an association between intake of high-fat high-sugar diet, variations in peripheral dopamine precursor availability and dopamine-dependent cognition in humans
PubMed ID: 33270945
APTD studies linking dopamine precursor availability (pDAP) to working memory and reinforcement learning provide robust evidence Phe/Tyr influence central dopamine chemistry.
- Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial
PubMed ID: 34344399
Sapropterin increased Phe tolerance while maintaining control in young children with PKU—clinical intervention that supports healthier brain biochemistry.
- Improving phenylalanine and micronutrients status of children with phenylketonuria: a pilot randomized study
PubMed ID: 34772434
Lowering blood Phe via caregiver education/low‑protein foods in children is directly relevant to preserving normal brain chemistry in PKU.
- Neuropsychiatric Function Improvement in Pediatric Patients with Phenylketonuria
PubMed ID: 37263523
Sapropterin lowered blood Phe and improved attention/executive outcomes — direct evidence Phe modulation affects brain function.
- Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial
PubMed ID: 39368841
Large (≈63%) reduction in blood Phe in PKU demonstrates strong capacity to modify Phe‑dependent brain chemistry.
- Cognition after a 4-week high phenylalanine intake in adults with phenylketonuria - a randomized controlled trial
PubMed ID: 38569786
Increased dietary Phe in treated adults with PKU degraded sustained attention — indicates sensitivity of brain function to Phe levels.
- Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial
PubMed ID: 34438354
Phenylalanine baseline levels predicted antidepressant response — direct human evidence tying Phe‑related biology to central nervous system treatment response.
- Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT)
PubMed ID: 1801541
Selegiline modifies monoamine metabolism (MAO‑B inhibition), demonstrating clinical impact of altering brain catecholamines.
- Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group
PubMed ID: 1327609
Comparing levodopa formulations showed altered bioavailability and off‑periods, linking formulation/pharmacokinetics to brain dopamine action.
- Selegiline in de novo parkinsonian patients: the Finnish study
PubMed ID: 8302307
Selegiline delayed L‑DOPA initiation and altered later dosing — shows meaningful manipulation of brain monoamine systems.
- Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom
PubMed ID: 8400928
Large randomized trial showed efficacy and differing side‑effect profiles of dopaminergic regimens—relevant to how manipulating dopamine affects clinical outcomes.
- Apomorphine test for dopaminergic responsiveness: a dose assessment study
PubMed ID: 8474482
Apomorphine injections produced motor responses and predicted levodopa response—demonstrates dopaminergic agonism effects on clinical function.
- Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial
PubMed ID: 8302306
Selegiline (MAO‑B inhibitor) improved motor and depressive scores—evidence that monoamine metabolism modulation influences brain chemistry and function.
- Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa
PubMed ID: 8105422
Cabergoline improved ADL and reduced off time—dopamine receptor agonism altering brain chemistry and daily function.
- Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial
PubMed ID: 8000101
Selegiline produced higher responder rates vs placebo; supports the concept that monoamine augmentation (dopamine) alters clinical state.
- A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up
PubMed ID: 8089666
Delaying levodopa by bromocriptine changed long-term motor complication profiles—clinical evidence of DA-system management effects.
- Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa
PubMed ID: 8527287
Tolcapone dose-dependently inhibited COMT and doubled levodopa exposure — direct pharmacologic modulation of dopamine metabolism.
- The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety
PubMed ID: 8526970
AMPT (tyrosine/phenylalanine hydroxylase inhibitor) and L‑dopa reversal directly demonstrate catecholamine-dependent CNS effects — highly relevant to phenylalanine as precursor.
- The effect of deprenyl and levodopa on the progression of Parkinson's disease
PubMed ID: 7486869
Deprenyl (selegiline) modified disease course/UPDRS in early PD — intervention on monoamine oxidase affects brain monoamines.
- Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom
PubMed ID: 8555803
Adding selegiline to levodopa associated with more motor complications and higher mortality — relevant to monoamine manipulation consequences.
- A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease
PubMed ID: 7715793
Dopamine agonists (pergolide/bromocriptine) added to levodopa improved motor scores — direct dopaminergic pharmacology.
- Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
PubMed ID: 8780092
Cabergoline (dopamine agonist) produced better ADL and motor scores and reduced levodopa dose — supports dopamine system modulation.
- Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study
PubMed ID: 8813223
Generic vs brand LD/CD had equivalent PK and motor responses — confirms dopaminergic pharmacology reproducibility.
- Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease
PubMed ID: 8726542
Ropinirole reduced off time as levodopa adjunct — drug evidence of changed dopaminergic tone.
- Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group
PubMed ID: 8572664
Large trial of deprenyl/tocopherol with clinical endpoints — affects monoamine systems relevant to brain chemistry.
- Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects
PubMed ID: 8739811
Tolcapone inhibited COMT and substantially increased levodopa availability — pharmacologic evidence for altering dopamine biochemistry.
- Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group
PubMed ID: 8572663
Observational trial results with deprenyl showing trends — indirect evidence of monoamine modulation.
- Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group
PubMed ID: 9392574
Entacapone increased percent 'on' time (clinical correlate of altered brain chemistry).
- SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa
PubMed ID: 10053226
Selegiline + L‑Dopa delayed need for dose escalation and reduced progression—strong clinical evidence that MAO‑B inhibition meaningfully alters dopamine system trajectory.
- Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study
PubMed ID: 10201413
Pramipexole improved motor scores and increased on‑time—dopamine agonism is a direct intervention on brain catecholamine signalling.
- Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group
PubMed ID: 9918342
Tolcapone showed levodopa‑sparing pharmacologic effects versus bromocriptine—demonstrates clinically relevant modulation of dopamine availability.
- Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD
PubMed ID: 11402115
L‑Dopa/pramipexole produced measurable DAT binding reductions—imaging evidence of altered dopamine transporter status and brain chemistry.
- Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD
PubMed ID: 11479392
Tolcapone adjunct improved UPDRS scores and reduced L‑Dopa needs—clinical corroboration that COMT inhibition alters brain dopaminergic balance with functional effects.
- Dopamine and semantic activation: an investigation of masked direct and indirect priming
PubMed ID: 14751003
Levodopa altered semantic priming time‑course — direct evidence that dopaminergic changes alter cognitive processing.
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
PubMed ID: 15262734
Pramipexole vs levodopa produced different clinical trajectories, implicating differing dopaminergic receptor effects.
- A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study
PubMed ID: 15235059
Ropinirole slowed putamen 18F‑DOPA decline ~33% vs L‑DOPA, a direct PET measure of altered dopaminergic metabolism.
- Levodopa: faster and better word learning in normal humans
PubMed ID: 15236398
Levodopa enhanced speed, success and retention of new‑word learning—strong functional evidence for dopaminergic modulation of cognition.
- The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study
PubMed ID: 15330687
Long-term cabergoline vs levodopa trial shows how different dopaminergic strategies shape clinical outcomes and brain dopaminergic function.
- Differential effects of subthalamic nucleus stimulation in advanced Parkinson disease on reaction time performance
PubMed ID: 16273395
STN DBS altered motor and reaction-time measures via modulation of basal ganglia circuits — indirect support for dopamine-related circuitry effects.
- Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)
PubMed ID: 15730352
Cabergoline effects in cocaine dependence reflect dopaminergic modulation of reward pathways relevant to brain chemistry.
- A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study
PubMed ID: 15710852
Rasagiline add-on showed clinically significant reductions in off-time → supports meaningful dopaminergic biochemical effects.
- Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
PubMed ID: 15766996
Rasagiline (MAO-B inhibitor) altered dopaminergic tone and reduced off-time → clear modulation of brain catecholamine metabolism.
- Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations
PubMed ID: 15595934
Entacapone added to levodopa/DDCI improved ADL and motor scores → pharmacologic augmentation of levodopa availability supports catecholaminergic function.
- Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment
PubMed ID: 15970632
Stalevo provided equivalent symptom control to separate tablets with high patient preference → demonstrates effective combined dopaminergic pharmacotherapy.
- Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease
PubMed ID: 17407630
Selegiline (MAO‑B inhibitor) adjunct altered dopaminergic functioning and reduced 'off' time—strong direct dopaminergic pathway evidence.
- Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients
PubMed ID: 17094103
Entacapone prolongs levodopa action and meaningfully increases 'on' time—clear manipulation of DA availability.
- Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study
PubMed ID: 17618525
Ropinirole adjunct improved motor scores and reduced off-time—direct dopaminergic pharmacology impact.
- Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease
PubMed ID: 17115380
Large trial demonstrating clear symptomatic benefit of dopamine agonists—evidence of dopaminergic system modulation.
- Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
PubMed ID: 18846551
Entacapone addition improved QoL/ADL—evidence that altering dopamine metabolism changes clinical state.
- Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease
PubMed ID: 19058133
LCE produced symptomatic advantages without increasing complications—a practical demonstration of modulating dopamine availability.
- New approach to the rehabilitation of post-stroke focal cognitive syndrome: effect of levodopa combined with speech and language therapy on functional recovery from aphasia
PubMed ID: 19268976
Levodopa enhanced language relearning after stroke—evidence of dopamine's role in plasticity/brain chemistry.
- Dopamine, paranormal belief, and the detection of meaningful stimuli
PubMed ID: 19642883
Acute levodopa effects on sensitivity and bias show clear dopaminergic influence on neural processing.
- Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study
PubMed ID: 20502133
Tolcapone as L‑dopa adjunct reduced OFF time/increased ON time by altering dopamine availability — mechanistic relevance to precursor pathways.
- Long-term efficacy of rasagiline in early Parkinson's disease
PubMed ID: 20504210
Long-term rasagiline observational data indicating sustained symptomatic benefit via monoamine oxidase-B inhibition.
- Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease
PubMed ID: 20669317
Pramipexole ER (dopamine agonist) improved motor/ADL measures → demonstrates functional consequences of dopaminergic modulation.
- Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets
PubMed ID: 20545388
Levodopa's behavior‑modifying effect in cocaine dependence indicates functional dopaminergic changes relevant to brain chemistry.
- Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease
PubMed ID: 20669296
Melevodopa/carbidopa produced clinically relevant changes in OFF time and levodopa exposure — supports importance of dopaminergic availability.
- Levodopa-carbidopa may improve vision loss in indirect traumatic optic neuropathy
PubMed ID: 20649490
Levodopa added to steroids increased chance of visual recovery after optic nerve injury — clinical evidence of dopaminergic effect on neural recovery.
- L-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children
PubMed ID: 21463967
Levodopa improved RLS/PLMS — demonstrates clinical effect of dopaminergic manipulation on CNS function.
- Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease
PubMed ID: 22609619
Acute levodopa impaired motor cortex plasticity in subgroups — mechanistic evidence that dopamine dosing alters cortical plasticity.
- Dopamine modulates reward system activity during subconscious processing of sexual stimuli
PubMed ID: 22395731
Levodopa pharmacologic challenge altered reward-circuit activation — imaging evidence that dopamine manipulations change brain chemistry/function.
- l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson's disease
PubMed ID: 22343069
Levodopa reduced ventral putamen activation correlated with learning changes — further evidence dopamine changes circuit activity.
- Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial
PubMed ID: 22316635
Pardoprunox (dopaminergic agent) reduced OFF time and improved UPDRS — pharmacologic dopamine modulation with clinical impact.
- Effects of L-dopa during auditory instrumental learning in humans
PubMed ID: 23285070
Acute L‑dopa changed cortical activation during learning—direct CNS dopaminergic modulation evidence.
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
PubMed ID: 24361112
Continuous levodopa infusion markedly reduced OFF time and lowered plasma variability — strong evidence that changing dopamine bioavailability alters clinical state.
- Dopamine modulates reward-related vigor
PubMed ID: 23419875
Clear human evidence that dopaminergic manipulation (L‑DOPA) modulates vigor and reward processing—direct support for dopamine‑related brain chemistry effects.
- Genetic variation in the human brain dopamine system influences motor learning and its modulation by L-Dopa
PubMed ID: 23613810
Genetic moderation of L‑Dopa effects on motor learning and plasticity demonstrates dopaminergic biology shaping brain function.
- Dopamine restores reward prediction errors in old age
PubMed ID: 23525044
L‑Dopa restored reward‑prediction signaling and improved learning with neural correlates—strong support for dopamine‑mediated brain chemistry modulation.
- Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease
PubMed ID: 23576623
PET evidence that levodopa increases striatal dopamine turnover — direct mechanistic support for catecholaminergic chemistry.
- Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients
PubMed ID: 25588353
Long‑term LCIG shows sustained dopaminergic clinical effects—evidence of long‑term modulation of brain chemistry.
- Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off
PubMed ID: 26347184
Entacapone improves levodopa efficacy via COMT inhibition—clear pharmacologic impact on dopamine availability.
- Clinical efficacy of istradefylline versus rTMS on Parkinson's disease in a randomized clinical trial
PubMed ID: 26393386
Istradefylline and rTMS modulated motor function alongside dopaminergic therapy—indirectly tied to brain chemistry.
- Antipsychotics decrease response confidence
PubMed ID: 27222269
Comparative study (haloperidol vs L‑DOPA) shows how dopamine modulation alters confidence—direct brain chemistry relevance.
- Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers
PubMed ID: 26626430
PK studies of extended‑release carbidopa–levodopa characterize dopamine precursor pharmacology.
- Dopamine Increases a Value-Independent Gambling Propensity
PubMed ID: 27149935
L‑DOPA increased baseline gambling propensity in healthy adults—demonstrates direct dopaminergic behavioral modulation.
- A single dose of L-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease
PubMed ID: 27718013
Single L‑DOPA dose produced measurable changes in latent inhibition and perceptual experience—robust dopamine‑related effect.
- Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease
PubMed ID: 27733560
Inhaled levodopa produced much faster plasma levels and rapid motor improvement—direct evidence of dopamine precursor pharmacodynamics.
- A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease
PubMed ID: 27090868
Self‑administered inhaled levodopa produced rapid motor benefit and reduced OFF time—clear dopaminergic effect.
- Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
PubMed ID: 26817533
Continuous intestinal levodopa reduced OFF time and dyskinesia—sustained modulation of brain dopamine signaling.
- The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis
PubMed ID: 26882318
Rotigotine (dopamine agonist) reduced OFF time and increased comfortable ON time—direct dopaminergic pharmacology.
- Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)
PubMed ID: 28833562
Extended‑release amantadine altered dyskinesia/ON time consistent with modulation of dopaminergic circuits; indirect support.
- Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial
PubMed ID: 28027332
Duplicate: opicapone reduced OFF time by altering levodopa metabolism (ties to dopamine turnover).
- Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials
PubMed ID: 29164312
Adjunct rotigotine produced motor improvements — supports dopaminergic pathway modulation.
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial
PubMed ID: 28604926
Duplicate: amantadine ER impacts dopamine‑related dyskinesia (see above).
- Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
PubMed ID: 28211816
Duplicate entry justified by strong levodopa PK/variability reduction (see above).
- Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study
PubMed ID: 29748109
Duplicate: rasagiline adjunct affects MAO‑B/dopamine turnover (see above).
- Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease
PubMed ID: 29570853
Long‑term LCIG maintained motor on‑time and lowered medication needs — sustained dopaminergic modulation.
- Amisulpride and l-DOPA modulate subcortical brain nuclei connectivity in resting-state pharmacologic magnetic resonance imaging
PubMed ID: 31880365
L‑DOPA reliably altered midbrain/striatal functional connectivity — mechanistic evidence for neurotransmitter effects.
- L-DOPA improves extinction memory retrieval after successful fear extinction
PubMed ID: 31243481
Post‑extinction L‑DOPA effects on extinction memory show dopamine's role in memory consolidation and brain chemistry.
- L-DOPA enhances neural direction signals in younger and older adults
PubMed ID: 36243268
Direct L‑DOPA probe showing modulation of hippocampal/retrosplenial signals — strong mechanistic link to catecholaminergic brain chemistry that phenylalanine feeds into.
- L-DOPA and oxytocin influence the neural correlates of performance monitoring for self and others
PubMed ID: 38286857
L‑DOPA modulation of ventral striatum and pregenual ACC signals demonstrates direct dopaminergic impact on brain chemistry.
- Levodopa Impairs the Energy Metabolism of the Basal Ganglia In Vivo
PubMed ID: 38366778
Levodopa caused major changes in basal ganglia energy metabolites—substantial biochemical impact in the brain.
- Effects of supplementary Da Dingfeng Zhu therapy on patients with Parkinson's disease of liver-kidney yin deficiency pattern
PubMed ID: 38518544
Herbal add‑on increased serum dopamine and improved clinical PD measures — evidence of altering central/peripheral monoamine biology.
Metabolism (35)
- Dose-response effects of dietary protein on muscle protein synthesis during recovery from endurance exercise in young men: a double-blind randomized trial
PubMed ID: 32359142
Clear evidence that dietary phenylalanine from protein contributes to positive whole-body net protein balance and increases myofibrillar protein synthesis after exercise.
- Home delivery of dietary products in inherited metabolic disorders reduces prescription and dispensing errors
PubMed ID: 16961684
PKU dietary‑product delivery trial: maintaining plasma phenylalanine control—direct metabolic management relevance.
- Randomized controlled trial of a protein substitute with prolonged release on the protein status of children with phenylketonuria
PubMed ID: 24724767
PKU trial demonstrates clinically relevant management of phenylalanine exposure and effects on protein-status — directly relevant to metabolic support in that condition.
- Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses
PubMed ID: 28353407
Genetic/pharmacogenomic study linked ACY3 and baseline N-acetylphenylalanine/phenylalanine levels to drug response — indicates phenylalanine metabolites as relevant metabolic biomarkers.
- Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997
PubMed ID: 29226610
Large prospective cohort: higher circulating phenylalanine was linked to greater future heart‑failure risk — important metabolic association (signal of risk).
- Efficacy of a New Low-Protein Multimedia Diet App for PKU
PubMed ID: 35683982
PKU mobile app improved Phe calculation confidence and modestly affected management — supports metabolic self‑management.
- Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial
PubMed ID: 39368841
Sepiapterin produced a large, safe reduction in blood Phe in PKU — clear metabolic benefit in Phe‑related disorder.
- Type 3 resistant starch from Canna edulis reduce lipid levels in patients with mild hyperlipidemia through altering gut microbiome: A double- blind randomized controlled trial
PubMed ID: 38825157
12‑week resistant starch supplement changed gut microbiome and metabolites including phenylalanine metabolism and lowered cholesterol—links Phe pathways to metabolic health.
- A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study
PubMed ID: 15235059
Ropinirole slowed putamen 18F‑DOPA decline ~33% vs L‑DOPA over 2 years—suggesting a metabolic/neurochemical preservation effect.
- Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the L-dopa
PubMed ID: 16219327
Study showed differences in plasma lipid peroxidation and correlations with L-dopa dose → suggests dopaminergic therapy relates to oxidative/metabolic markers.
- Dose-Dependent Increases in Whole-Body Net Protein Balance and Dietary Protein-Derived Amino Acid Incorporation into Myofibrillar Protein During Recovery from Resistance Exercise in Older Men
PubMed ID: 30722014
Shows dose-dependent incorporation of dietary Phe into muscle and improved whole-body net protein balance — directly relevant to metabolic/anabolic health.
- Serum metabolite profiling yields insights into health promoting effect of A. muciniphila in human volunteers with a metabolic syndrome
PubMed ID: 34812127
A. muciniphila supplementation lowered several Phe-derived metabolites and produced metabolomic shifts (ketones, acylcarnitines) consistent with altered substrate metabolism.
- The effects of short-term parenteral nutrition on human liver protein and amino acid metabolism during laparoscopic surgery
PubMed ID: 9406129
Short-term TPN raised hepatic free essential AAs (including Phe)—clear effect on amino-acid availability and hepatic amino-acid pool.
- Weight-loss diets and 2-y changes in circulating amino acids in 2 randomized intervention trials
PubMed ID: 26791187
Large weight‑loss trials: reductions in aromatic AAs (including Phe) correlated with improved insulin sensitivity — strong metabolic association evidence.
- Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study
PubMed ID: 26887663
Randomized metformin trial lowered phenylalanine vs placebo — direct intervention effect on circulating Phe linked to metabolic benefit.
- Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
PubMed ID: 29728717
Large diabetes cohort: baseline Phe/Tyr associated with vascular outcomes and mortality — robust epidemiologic metabolic associations.
- Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?
PubMed ID: 24627569
Baseline phenylalanine predicted development of impaired fasting glucose after atenolol; strong observational link between circulating Phe and metabolic risk.
- Ornithine alpha-ketoglutarate improves wound healing in severe burn patients: a prospective randomized double-blind trial versus isonitrogenous controls
PubMed ID: 10890617
Ornithine α-KG reduced plasma phenylalanine and reduced protein breakdown markers in burn patients — supports metabolic/ protein-sparing effects linked to Phe changes.
- Global testing of shifts in metabolic phenotype
PubMed ID: 30830386
Metabolomics analysis shows phenylalanine/tyrosine pathways differ by obesity and change with weight-loss interventions — supports role of Phe pathways in metabolic health.
- Weizmannia coagulans BC99 regulates oxidative stress and serum metabolic pathways to improve allergic rhinitis: a randomized, double-blind, placebo-controlled trial
PubMed ID: 41208993
Probiotic RCT modulated serum phenylalanine metabolism and produced clinical benefit (allergic rhinitis) — supports systemic metabolic impact of altered Phe pathways.
- ACE inhibitory casein peptide lowers blood pressure and reshapes gut microbiota in a randomized double blind placebo controlled trial
PubMed ID: 40263513
Randomized placebo-controlled trial: casein peptides lowered serum phenylalanine (~10%) and produced clear physiological benefits (BP reduction) — strong direct evidence that modulating Phe-related biochemistry affects systemic metabolism.
- Nutritional evaluation of children with phenylketonuria
PubMed ID: 10592130
Cross‑sectional PKU children study: phenylalanine‑restricted diets produced inadequate calories/minerals and lower growth—direct metabolic/nutritional impact of Phe management.
- Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial
PubMed ID: 27413125
In PKU, replacing AA medical foods with GMP foods changed fasting Phe and dietary Phe intake—directly relevant to Phe metabolic management.
- Pre-sleep Protein Ingestion Increases Mitochondrial Protein Synthesis Rates During Overnight Recovery from Endurance Exercise: A Randomized Controlled Trial
PubMed ID: 36857005
Pre‑sleep protein increased overnight myofibrillar and mitochondrial protein synthesis after exercise — supports metabolic recovery/overnight metabolism.
- [Improvement of the pre-hypertensive inherited cardiac dearangements with phenylalanine in essential hypertension]
PubMed ID: 9596981
Daily phenylalanine (1 g) reduced left ventricular mass and wall thickness in adolescents (meaningful systemic/metabolic/cardio effect).
- Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia
PubMed ID: 10868832
Large randomized trial: nateglinide (a D‑phenylalanine derivative) improved mealtime glycemic control and HbA1c dose‑dependently — direct metabolic benefit from a Phe‑based drug.
- Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes
PubMed ID: 11092289
Nateglinide (D-phenylalanine derivative) improved HbA1c and glucose control — structural relevance to Phe scaffold and metabolic pharmacology.
- Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia
PubMed ID: 12213867
Large randomized trial showing modest HbA1c/FPG reductions with nateglinide — strong metabolic evidence for the derivative.
- Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients
PubMed ID: 12047396
Adding nateglinide to metformin improved glycemic control in a large RCT — substantial metabolic effect from a Phe-derived drug.
- The Resource Mothers Study of Maternal Phenylketonuria: preliminary findings
PubMed ID: 15159645
PKU pregnancy study: earlier maternal phenylalanine control — direct metabolic benefit in Phe management.
- The daily phenylalanine requirement of healthy Indian adults
PubMed ID: 16762944
Directly quantifies daily phenylalanine requirement in healthy adults using validated isotope methods—foundational metabolic evidence.
- Methionine requirement of the enterally fed term infant in the first month of life in the presence of cysteine
PubMed ID: 22492372
Infant methionine requirement estimated using phenylalanine tracer — direct AA‑metabolism data.
- Unaffected arm muscle hypercatabolism in dysphagic subacute stroke patients: the effects of essential amino acid supplementation
PubMed ID: 25431770
EAA supplementation shifted muscle A−V Phe from release to uptake — metabolic/anabolic relevance.
- Carbohydrate coingestion delays dietary protein digestion and absorption but does not modulate postprandial muscle protein accretion
PubMed ID: 24628553
Phenylalanine tracer revealed age‑related reductions in dietary Phe availability and effects of macronutrients on appearance.
- Phenylalanine requirements of enterally fed term and preterm neonates
PubMed ID: 25926506
Neonatal phenylalanine requirement estimates are direct evidence of Phe's essential metabolic role in growth/health.
Mood balance (27)
- Dopamine Depletion Reduces Food-Related Reward Activity Independent of BMI
PubMed ID: 26450814
APTD blunted reward responses — reward processing is tightly linked to mood and anhedonia.
- Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT)
PubMed ID: 1801541
Selegiline produced symptomatic improvements (affecting dopaminergic tone) — directly relevant to mood modulation.
- Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial
PubMed ID: 8302306
Selegiline improved depressive scores in newly treated PD patients — direct evidence that monoamine augmentation benefits mood.
- The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety
PubMed ID: 8526970
AMPT made volunteers more anxious and less calm; L‑dopa reversed these mood effects → strong catecholamine link to mood.
- The effect of deprenyl and levodopa on the progression of Parkinson's disease
PubMed ID: 7486869
Deprenyl (MAO‑B inhibitor) affects monoamine metabolism and produced sustained clinical benefit in early PD; MAO inhibition can influence mood.
- Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group
PubMed ID: 8572664
Selegiline trial showed systemic effects and increased mortality but indicates strong monoaminergic manipulation relevant to mood.
- SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa
PubMed ID: 10053226
Selegiline + L‑Dopa produced durable clinical benefits and delayed escalation—MAO‑B inhibition preserves dopamine/NE and is relevant to mood support.
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
PubMed ID: 15262734
Pramipexole (dopamine agonist) produced clinical differences vs levodopa that can translate to mood/QoL effects.
- A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study
PubMed ID: 15235059
Slower dopaminergic decline with ropinirole may support longer‑term neurochemical balance relevant to mood.
- Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy
PubMed ID: 15613141
Adding dopamine agonists improved mood in depressed PD patients → supports dopaminergic modulation of mood.
- Dopamine modulates reward system activity during subconscious processing of sexual stimuli
PubMed ID: 22395731
Levodopa increased limbic/reward activation to subliminal sexual cues — consistent with mood/reward enhancement.
- Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial
PubMed ID: 24928805
Large levodopa trial showed small but lasting QoL/mobility gains—translatable to mood/well‑being (indirect).
- Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study
PubMed ID: 35927580
L-DOPA challenge reduced anhedonia and increased corticostriatal reward connectivity in inflamed depressed patients—direct mood benefit signal.
- Effects of Dopaminergic Therapy with Levodopa (L-DOPA) on Fear and Anxiety-Related Circuits and Symptoms in Patients with Depression and Higher Inflammation
PubMed ID: 41478464
L‑DOPA reduced state anxiety and PTSD symptoms in patients with higher inflammation—direct mood benefit.
- Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson's disease
PubMed ID: 40434674
Synbiotic with levodopa increased BDNF and improved nonmotor scores that include mood components.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Removal of Phe/Tyr reduced stimulant effects and lowered mania ratings — shows precursor availability strongly affects dopamine-related mood states (inverse evidence).
- Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial
PubMed ID: 34438354
Lower baseline serum phenylalanine predicted better antidepressant response — direct associative evidence linking Phe biology to mood outcomes.
- Blue Monday: Co-occurring Stimulant Use and HIV Persistence Predict Dysregulated Catecholamine Synthesis
PubMed ID: 33165125
Study directly links P/T ratio (phenylalanine/tyrosine balance) to depression screening odds—strongly relevant to mood.
- Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept
PubMed ID: 22162828
Metabolomic evidence that a phenylalanine‑pathway marker (4‑HPLA) associates with antidepressant response—supports a link to mood/monoamine biology (indirect).
- Administration of serotonin inhibitor p-Chlorophenylalanine induces pessimistic-like judgement bias in sheep
PubMed ID: 20833479
Direct animal evidence that pharmacologic manipulation of a phenylalanine-related compound (pCPA) alters serotonin-dependent affective bias (clear link to mood; though animal and pharmacologic, not dietary Phe).
- Brain glucose uptake is associated with endogenous glucose production in obese patients before and after bariatric surgery and predicts metabolic outcome at follow-up
PubMed ID: 30098134
Circulating Phe associated with brain metabolic activity; such links support a role for Phe-related pathways in mood/cognition.
- Elevated serum prolactin concentrations in phenylketonuric patients on a 'loose diet'
PubMed ID: 9509074
PKU patients with elevated Phe had markedly altered dopamine/prolactin and menstrual dysfunction—strong evidence Phe affects mood‑relevant neurochemistry.
- Dopamine and light: effects on facial emotion recognition
PubMed ID: 28633582
Direct manipulation of Phe/Tyr availability altered emotion recognition (improved sad-face processing) independent of mood — strong mechanistic link to mood-related cognition via catecholamines.
- Intellectual development in 12-year-old children treated for phenylketonuria
PubMed ID: 1985428
Higher developmental Phe linked to worse cognitive and achievement scores; PKU long‑term Phe exposure can affect mood and psychiatric outcomes (strong clinical relevance).
- Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
PubMed ID: 29653686
Pegvaliase produced neuropsychiatric/symptomatic improvements in adults with PKU as blood Phe fell—strong clinical evidence that Phe levels affect mood in PKU.
- Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
PubMed ID: 30366815
Pegvaliase lowers blood Phe with associated neuropsychiatric/functional improvements in PKU, supporting mood benefits.
- Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial
PubMed ID: 29628378
Marked Phe rises after withdrawal suggest mood/neuro effects are linked to Phe control.
Energy & Fatigue (23)
- Levodopa: faster and better word learning in normal humans
PubMed ID: 15236398
Improved learning speed/retention on levodopa suggests reduced cognitive effort per unit learning (less fatigue).
- Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease
PubMed ID: 20669317
Pramipexole ER improved motor function and reduced need for rescue levodopa → likely translates to increased functional energy.
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
PubMed ID: 24361112
Continuous jejunal levodopa infusion reduced Off time and increased On time → patients have more periods of good function/energy.
- Dopamine modulates reward-related vigor
PubMed ID: 23419875
L‑DOPA amplified reward‑related action vigor—direct evidence supporting increased behavioral energy/vigor.
- Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial
PubMed ID: 24928805
Large levodopa initiation trial improved patient‑rated mobility/QoL — likely perceived as increased energy/vitality.
- Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
PubMed ID: 28211816
Reduced intra‑subject levodopa variability and increased ON time plausibly reduce fluctuations that contribute to mental fatigue.
- Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease
PubMed ID: 40736131
Foslevodopa increased ON time and improved QoL—patients report more 'on' functioning and energy.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Precursor depletion reduced dopamine neurotransmission and stimulant effects — inverse evidence that precursor availability affects mental fatigue/arousal.
- Dopamine Depletion Reduces Food-Related Reward Activity Independent of BMI
PubMed ID: 26450814
APTD blunted reward signaling which can reduce motivational drive and increase subjective cognitive fatigue.
- Dopamine depletion effects on cognitive flexibility as modulated by tDCS of the dlPFC
PubMed ID: 31494070
APTD slowed reaction times — objective sign of reduced activation/greater mental fatigue.
- Blue Monday: Co-occurring Stimulant Use and HIV Persistence Predict Dysregulated Catecholamine Synthesis
PubMed ID: 33165125
Altered catecholamine precursor metabolism (P/T) associated with depression risk and likely with fatigue-related symptoms.
- Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
PubMed ID: 15766996
Rasagiline reduced daily off-time and increased on-time → patients experience more functional 'on' time (experienced as energy/activity).
- A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study
PubMed ID: 15710852
Rasagiline add-on decreased off time in levodopa-treated patients → supports increased functional energy during the day.
- Differential effects of subthalamic nucleus stimulation in advanced Parkinson disease on reaction time performance
PubMed ID: 16273395
Improved reaction times and motor performance with STN-DBS imply reductions in cognitive/motor fatigability.
- Fatigue in levodopa-naive subjects with Parkinson disease
PubMed ID: 18695158
Levodopa groups showed smaller increases in fatigue scores than placebo — direct evidence.
- Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD
PubMed ID: 11479392
Tolcapone adjunct produced functional improvement and reduced L‑Dopa requirements—likely to translate to better daytime energy/drive.
- Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study
PubMed ID: 10201413
Pramipexole increased on‑time and reduced off periods—clinically meaningful improvements in daily functioning and perceived energy.
- Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial
PubMed ID: 10617168
Nightly levodopa produced rapid, significant improvements in sleep quality in RLS patients—better sleep reduces daytime mental fatigue.
- The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety
PubMed ID: 8526970
AMPT caused sleepiness (mental fatigue) reversed by L‑dopa → strong evidence catecholamines reduce mental fatigue.
- Neuropsychiatric Function Improvement in Pediatric Patients with Phenylketonuria
PubMed ID: 37263523
Attention/executive improvements with sapropterin suggest reduced cognitive load/fatigue in PKU children.
- Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
PubMed ID: 30366815
Normalization of blood Phe may reduce cognitive fatigue in PKU; study documents neuropsychiatric improvements alongside Phe fall.
- A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria
PubMed ID: 25533024
Reduction in inattentive symptoms in sapropterin‑responsive PKU suggests reduced cognitive strain/fatigue in some patients.
- Intellectual development in 12-year-old children treated for phenylketonuria
PubMed ID: 1985428
High Phe during critical periods is associated with poorer cognitive stamina and school performance; better Phe control linked to less cognitive fatigue in PKU.
Wellbeing (21)
- Dopamine and light: effects on facial emotion recognition
PubMed ID: 28633582
Altered emotion recognition and faster responses with Phe/Tyr depletion indicate Phe availability affects affective processing that contributes to well‑being.
- Intellectual development in 12-year-old children treated for phenylketonuria
PubMed ID: 1985428
Evidence that uncontrolled Phe during development harms cognitive/functional outcomes; control of Phe is associated with better overall function/well‑being in PKU.
- Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
PubMed ID: 29653686
Pegvaliase treatment led to clinical symptom improvements in adults with PKU as blood Phe fell—strong evidence that manipulating Phe improves well‑being in PKU.
- Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
PubMed ID: 30366815
Sustained blood Phe reductions with pegvaliase were associated with clinical improvements and likely better well‑being in PKU patients.
- Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
PubMed ID: 8780092
Cabergoline improved ADL and motor scores and reduced levodopa dose — clinical benefit that can raise well‑being.
- SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa
PubMed ID: 10053226
Selegiline + L‑Dopa delayed need for dose escalation and reduced progression—sustained symptomatic benefit correlates with better overall well‑being.
- Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD
PubMed ID: 11479392
Tolcapone adjunct produced clear functional and global improvements—likely to translate into improved quality of life and well‑being.
- Levodopa: faster and better word learning in normal humans
PubMed ID: 15236398
Levodopa improved learning outcomes in healthy subjects, which can translate into subjective benefit during cognitive tasks.
- Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
PubMed ID: 18846551
Entacapone added to levodopa produced statistically significant QoL and ADL improvements in early PD.
- [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study]
PubMed ID: 19156087
Switch to Stalevo improved EQ‑5D QoL scores and ON time in patients—patient‑reported well‑being gains.
- Long-term stability of effects of subthalamic stimulation in Parkinson's disease: Indian Experience
PubMed ID: 20976738
5‑year follow‑up of bilateral STN stimulation showed lasting motor and QoL benefits.
- Long-term efficacy of rasagiline in early Parkinson's disease
PubMed ID: 20504210
Long-term rasagiline treatment associated with sustained symptomatic benefit and tolerability → improved overall well-being.
- Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease
PubMed ID: 24055014
ER carbidopa/levodopa improved motor/ADL and PDQ‑39 quality of life in early PD—direct QoL evidence in a clinical population.
- Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial
PubMed ID: 24928805
Large pragmatic trial: starting levodopa produced small but lasting mobility and QoL advantages (strong clinical signal).
- Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study
PubMed ID: 29748109
Rasagiline produced modest PDQ‑39 improvement (quality of life), indicating improved well‑being via dopaminergic mechanisms.
- Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease
PubMed ID: 29570853
Long‑term LCIG reported durable improvements in motor on‑time and quality of life — clinically meaningful well‑being gains tied to dopamine therapy.
- Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial
PubMed ID: 39790009
Opicapone added to levodopa improved motor scores and patient‑reported global improvement.
- Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson's disease
PubMed ID: 40434674
Synbiotic+levodopa improved motor/nonmotor scores and biomarkers, consistent with better overall well‑being.
- Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease
PubMed ID: 40736131
Phase‑3 foslevodopa program increased ON time, reduced OFF time, and improved PDQ‑39 QoL scores substantially.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Precursor depletion reduced stimulant effects and mania — shows precursor availability powerfully affects affective state and thus well-being (inverse evidence).
- Dopamine Depletion Reduces Food-Related Reward Activity Independent of BMI
PubMed ID: 26450814
APTD blunted reward signaling — reduced reward/pleasure can lower well-being, demonstrating relevance of Phe/Tyr to affect.
Mental clarity (20)
- A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria
PubMed ID: 25533024
Sapropterin-responsive PKU patients had improved inattentive/attention-related symptoms after lowering blood Phe, supporting clearer cognition.
- Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients
PubMed ID: 21491106
PKU patients showed executive deficits and acute Phe load related to frontal function → direct link between Phe control and mental clarity.
- Intellectual development in 12-year-old children treated for phenylketonuria
PubMed ID: 1985428
Childhood blood phenylalanine strongly correlates with later cognitive/achievement outcomes; high Phe impairs mental clarity in PKU.
- Dopamine and light: effects on facial emotion recognition
PubMed ID: 28633582
APTD (lowered Phe/Tyr) changed emotion processing and sped reactions — strong dopamine-linked evidence that Phe availability influences cognitive-emotional clarity.
- Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
PubMed ID: 30366815
Directly lowers blood phenylalanine in PKU; Phe normalization is linked to improved neuropsychiatric function and clearer cognition.
- Dopamine depletion effects on cognitive flexibility as modulated by tDCS of the dlPFC
PubMed ID: 31494070
APTD slowed reaction times and altered cognitive flexibility — relevant to processing speed/clarity.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Removing Phe/Tyr reduced dopamine-mediated effects and mania — strong evidence that precursor availability affects cognitive/mental state (inverse evidence).
- Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease
PubMed ID: 40736131
Foslevodopa trials improved ON time and QoL; improved motor/nonmotor control can support subjective mental clarity.
- The efficacy of levodopa/carbidopa/entacapone on cognitive function in moderate to advanced Parkinson's disease and its relationship with peripheral inflammatory cytokines
PubMed ID: 40108546
Entacapone+levodopa improved MoCA (cognition), which can manifest as improved mental clarity.
- Differential effects of subthalamic nucleus stimulation in advanced Parkinson disease on reaction time performance
PubMed ID: 16273395
DBS study showed improved reaction times and motor performance -> proxy for improved mental/psychomotor clarity.
- Levodopa: faster and better word learning in normal humans
PubMed ID: 15236398
Five days of levodopa improved new‑word learning speed and retention, consistent with clearer processing.
- Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD
PubMed ID: 11479392
Tolcapone+L‑Dopa improved clinician-rated function and reduced symptoms—indirect evidence for clearer cognition via dopaminergic support.
- The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety
PubMed ID: 8526970
AMPT-induced sleepiness/negative mood reversed by L‑dopa → supports catecholamine-mediated improvements in alertness/clarity.
- Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial
PubMed ID: 39368841
Sepiapterin markedly lowered blood Phe in PKU (large effect) — biochemical change likely to support mental clarity in Phe-sensitive individuals.
- Neuropsychiatric Function Improvement in Pediatric Patients with Phenylketonuria
PubMed ID: 37263523
Sapropterin in PKU lowered blood Phe and improved attention/executive symptoms, supporting clearer cognitive function.
- Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial
PubMed ID: 27413125
Dietary changes in PKU altered fasting Phe; managing Phe exposure can benefit cognition/clarity (clinical PKU relevance).
- Preliminary evidence for an association between intake of high-fat high-sugar diet, variations in peripheral dopamine precursor availability and dopamine-dependent cognition in humans
PubMed ID: 33270945
APTD reduced working‑memory performance in a subgroup; shows dopamine‑precursor availability (Phe/Tyr) affects cognitive clarity.
- Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial
PubMed ID: 29628378
Stopping pegvaliase caused large Phe rises (worse brain biochemistry) — implies Phe control affects cognitive clarity.
- Blue Monday: Co-occurring Stimulant Use and HIV Persistence Predict Dysregulated Catecholamine Synthesis
PubMed ID: 33165125
Higher P/T ratio linked to depressive symptoms and altered catecholamine precursor metabolism—implicates phenylalanine/tyrosine balance in cognitive clarity.
- Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
PubMed ID: 29653686
Pegvaliase lowering of blood Phe in PKU produced symptomatic/neuropsychiatric improvements, implying Phe control improves clarity.
Muscle maintenance (25)
- Myofibrillar and Mitochondrial Protein Synthesis Rates Do Not Differ in Young Men Following the Ingestion of Carbohydrate with Milk Protein, Whey, or Micellar Casein after Concurrent Resistance- and Endurance-Type Exercise
PubMed ID: 30698725
Co‑ingesting ~20 g protein after concurrent exercise increased muscle protein synthesis vs carbs alone (phenylalanine tracer used) — direct relevance to muscle maintenance.
- Whey protein stimulates postprandial muscle protein accretion more effectively than do casein and casein hydrolysate in older men
PubMed ID: 21367943
Whey produced faster phenylalanine appearance and almost doubled post‑meal muscle FSR vs casein in older men — strong evidence on dietary AA effects on MPS.
- Age and aerobic exercise training effects on whole body and muscle protein metabolism
PubMed ID: 14506079
Age/training study using phenylalanine tracer showed exercise increases mixed muscle protein synthesis — relevant to muscle maintenance.
- A moderate serving of high-quality protein maximally stimulates skeletal muscle protein synthesis in young and elderly subjects
PubMed ID: 19699838
Used labeled phenylalanine tracer to show moderate and large beef meals similarly increased mixed muscle fractional synthesis rate by ~46–50% — direct evidence Phe kinetics reflect postprandial MPS.
- Functional and metabolic effects of omega-3 polyunsaturated fatty acid supplementation and the role of β-hydroxy-β-methylbutyrate addition in chronic obstructive pulmonary disease: A randomized clinical trial
PubMed ID: 39181037
EPA/DHA (±HMB) altered phenylalanine whole-body production and increased lean soft tissue mass — supports link between AA kinetics and muscle maintenance.
- Four-week supplementation with a natural dietary compound produces favorable changes in body composition
PubMed ID: 10345151
Multi‑ingredient supplement including L‑phenylalanine preserved fat‑free mass during weight‑loss versus placebo—direct body‑composition outcome.
- No differences in muscle protein synthesis rates following ingestion of wheat protein, milk protein, and their protein blend in healthy, young males
PubMed ID: 33597056
Protein source study (phenylalanine tracer) showed similar stimulation of MPS across milk/wheat blends—indirect support for phenylalanine's role in postprandial MPS.
- Dose-response effects of dietary protein on muscle protein synthesis during recovery from endurance exercise in young men: a double-blind randomized trial
PubMed ID: 32359142
Direct tracer-based study showing dietary phenylalanine from protein was incorporated into muscle protein and higher protein doses increased myofibrillar protein synthesis and whole-body net balance.
- Dose-Dependent Increases in Whole-Body Net Protein Balance and Dietary Protein-Derived Amino Acid Incorporation into Myofibrillar Protein During Recovery from Resistance Exercise in Older Men
PubMed ID: 30722014
Direct tracer study showing dose-dependent incorporation of dietary Phe into muscle and higher postexercise protein doses increased FSR in older men.
- Ingestion of 20 g Whey or Canola Protein Does Not Further Increase Muscle Protein Synthesis Rates During Recovery From Resistance Exercise In Healthy, Young Females
PubMed ID: 41101508
Phenylalanine tracer used to measure mixed‑muscle protein synthesis after resistance exercise — directly relevant mechanistic evidence for muscle protein dynamics.
- Leucine supplementation of a low-protein mixed macronutrient beverage enhances myofibrillar protein synthesis in young men: a double-blind, randomized trial
PubMed ID: 24284442
Low‑protein plus high leucine matched 25 g whey for myofibrillar synthesis — shows how amino‑acid composition (tracked via Phe) affects MPS.
- Ingestion of Wheat Protein Increases In Vivo Muscle Protein Synthesis Rates in Healthy Older Men in a Randomized Trial
PubMed ID: 27440260
Large RCT showing differences in EAA peaks and myofibrillar synthesis across protein sources (phenylalanine-traced) — informative for dietary support of muscle maintenance.
- Effectiveness of essential amino acid supplementation in stimulating whole body net protein anabolism is comparable between COPD patients and healthy older adults
PubMed ID: 28285641
EAA-only drink produced substantially greater whole-body net protein gain (dietary Phe measured) — supports net anabolism relevant to muscle maintenance.
- Myofibrillar and Mitochondrial Protein Synthesis Rates Do Not Differ in Young Men Following the Ingestion of Carbohydrate with Whey, Soy, or Leucine-Enriched Soy Protein after Concurrent Resistance- and Endurance-Type Exercise
PubMed ID: 30698812
Study used phenylalanine tracer to quantify myofibrillar protein synthesis after concurrent exercise; direct measurement of muscle anabolic responses (indirect re: Phe supplement).
- Myofibrillar muscle protein synthesis rates subsequent to a meal in response to increasing doses of whey protein at rest and after resistance exercise
PubMed ID: 24257722
20 g whey maximally stimulated MPS; 40 g increased phenylalanine oxidation—evidence on the dose‑response of Phe‑containing proteins for muscle protein handling.
- Protein Ingestion before Sleep Increases Overnight Muscle Protein Synthesis Rates in Healthy Older Men: A Randomized Controlled Trial
PubMed ID: 28855419
40 g casein before sleep increased exogenous phenylalanine appearance and overnight myofibrillar protein synthesis more than lower doses—direct Phe‑kinetic evidence for muscle maintenance.
- Presleep dietary protein-derived amino acids are incorporated in myofibrillar protein during postexercise overnight recovery
PubMed ID: 28536184
Casein before sleep improved whole‑body protein net balance and dietary phenylalanine was incorporated into muscle (direct tracer evidence supporting muscle amino‑acid utilisation).
- Acute ingestion of a ketone monoester, whey protein, or their co-ingestion in the overnight postabsorptive state elicit a similar stimulation of myofibrillar protein synthesis rates in young males: a double-blind randomized trial
PubMed ID: 38215886
Study using phenylalanine tracer showed ketone drink and whey protein increased myofibrillar protein synthesis—directly relevant to muscle maintenance.
- Whey protein supplementation preserves postprandial myofibrillar protein synthesis during short-term energy restriction in overweight and obese adults
PubMed ID: 25644344
Phenylalanine tracer methods demonstrated whey protein preserved postprandial myofibrillar protein synthesis during calorie restriction (direct anabolic evidence).
- Unaffected arm muscle hypercatabolism in dysphagic subacute stroke patients: the effects of essential amino acid supplementation
PubMed ID: 25431770
EAA supplementation (measured via phenylalanine A−V) converted net muscle release to uptake — strong evidence that amino acids (incl. Phe as tracer) support muscle anabolism.
- Amino acid absorption and subsequent muscle protein accretion following graded intakes of whey protein in elderly men
PubMed ID: 22338070
(duplicate entry reaffirming whey dose effect on MPS measured by Phe tracer).
- Collagen Protein Ingestion during Recovery from Exercise Does Not Increase Muscle Connective Protein Synthesis Rates
PubMed ID: 37202878
Resistance exercise increased myofibrillar and connective protein synthesis; whey increased myofibrillar FSR vs placebo (tracer study) — supports muscle maintenance with protein intake.
- Algae Ingestion Increases Resting and Exercised Myofibrillar Protein Synthesis Rates to a Similar Extent as Mycoprotein in Young Adults
PubMed ID: 37716611
Algae proteins increased resting and postexercise MyoPS similarly to mycoprotein (measured with tracer including Phe) — supports muscle maintenance from dietary proteins.
- Pre-sleep Protein Ingestion Increases Mitochondrial Protein Synthesis Rates During Overnight Recovery from Endurance Exercise: A Randomized Controlled Trial
PubMed ID: 36857005
Pre‑sleep protein after endurance exercise increased overnight myofibrillar and mitochondrial protein synthesis (phenylalanine tracer) — strong support for overnight muscle maintenance.
- Casein Ingestion Does Not Increase Muscle Connective Tissue Protein Synthesis Rates
PubMed ID: 32195768
Dietary phenylalanine was incorporated into new connective tissue and exercise increased incorporation — direct tracer evidence of dietary Phe contributing to muscle/connective tissue.
Motivation & confidence (18)
- Bidirectional modulation of reward-guided decision making by dopamine
PubMed ID: 40439740
In healthy men L‑DOPA increased the influence of reward magnitude/probability on choices—clear enhancement of motivation signals.
- Dopamine Depletion Reduces Food-Related Reward Activity Independent of BMI
PubMed ID: 26450814
APTD blunted striatal reward responses to food — demonstrates catecholamine precursor impact on reward circuitry central to motivation.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Precursor depletion decreased stimulant effects and mania — strong inverse evidence that precursor availability modulates dopamine-related motivation/arousal.
- Dopamine and Temporal Discounting: Revisiting Pharmacology and Individual Differences
PubMed ID: 41136339
L‑DOPA reduced temporal discounting (greater valuation of delayed reward), consistent with increased goal‑directed motivation.
- L-DOPA and oxytocin influence the neural correlates of performance monitoring for self and others
PubMed ID: 38286857
L‑DOPA altered ventral striatal error‑related signals relevant to motivational processing.
- A selective effect of dopamine on information-seeking
PubMed ID: 33295870
L-DOPA reduced valence dependence of information-seeking (willingness-to-pay for info)—direct behavioral signal linked to motivated information-seeking.
- Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
PubMed ID: 28211816
More stable dopamine exposure and increased ON time may improve motivational drive in PD patients by reducing OFF periods.
- Dopamine modulates reward-related vigor
PubMed ID: 23419875
L‑DOPA strengthened the relationship between average reward rate and action vigor—strong evidence linking dopamine to motivation.
- Dopamine modulates reward system activity during subconscious processing of sexual stimuli
PubMed ID: 22395731
Levodopa increased nucleus accumbens and dorsal ACC activation to reward cues — neurobiological correlate of motivation.
- Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets
PubMed ID: 20545388
Levodopa improved outcomes in contingency‑managed cocaine dependence (increasing abstinence‑linked behavior) — suggests increased motivational drive from dopaminergic augmentation.
- Dopamine receptor D4 polymorphism predicts the effect of L-DOPA on gambling behavior
PubMed ID: 19914604
L‑DOPA increased gambling propensity in DRD4 7‑repeat carriers — strong behavioral motivation signal (genotype‑dependent).
- Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)
PubMed ID: 15730352
Cabergoline-treated cocaine-dependent participants had higher rates of cocaine-negative urines → suggests dopaminergic modulation of motivation/reward-related behavior.
- Levodopa: faster and better word learning in normal humans
PubMed ID: 15236398
Improved learning performance with levodopa can reflect increased engagement/motivation during training.
- Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
PubMed ID: 8780092
Cabergoline improved ADL and motor scores and reduced levodopa requirement — increased dopaminergic stimulation tied to motivation.
- Serotonin and dopamine differentially affect appetitive and aversive general Pavlovian-to-instrumental transfer
PubMed ID: 25034118
Tyrosine/phenylalanine depletion reduced appetitive PIT — direct behavioural evidence that Phe/tyrosine availability modulates motivation.
- Acute phenylalanine/tyrosine depletion reduces motivation to smoke cigarettes across stages of addiction
PubMed ID: 21775977
APTD robustly reduced smokers' willingness to work for nicotine, implicating Phe/Tyr in dopamine-mediated motivation.
- Intellectual development in 12-year-old children treated for phenylketonuria
PubMed ID: 1985428
Long‑term elevated Phe associated with worse cognitive/achievement outcomes — normalization could support motivation in PKU‑affected individuals.
- Elevated serum prolactin concentrations in phenylketonuric patients on a 'loose diet'
PubMed ID: 9509074
Altered dopamine in high‑Phe PKU supports that Phe levels can change neurotransmission underlying motivation.
Alertness (17)
- Dopamine depletion effects on cognitive flexibility as modulated by tDCS of the dlPFC
PubMed ID: 31494070
APTD slowed RTs and modulated cognitive flexibility; direct measure of alertness/processing speed change.
- Dopamine Depletion Reduces Food-Related Reward Activity Independent of BMI
PubMed ID: 26450814
APTD blunted reward-related striatal responses — changes in motivational salience influence alertness to stimuli.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Precursor depletion reduced stimulant effects and dopamine transmission — strong inverse evidence that precursor availability influences alertness/arousal.
- Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease
PubMed ID: 40736131
Increased ON time from continuous levodopa was associated with better sleep scores and daytime functioning (alertness).
- Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease
PubMed ID: 30992235
Inhaled levodopa produced more patients ON by 30 min vs placebo → rapid return to alert/functional state.
- Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial
PubMed ID: 30663606
Inhaled levodopa produced greater motor improvement at 30 minutes vs placebo → acute alerting effect likely.
- Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
PubMed ID: 28211816
LCIG reduced levodopa plasma variability and increased ON time — clinically plausibly linked to improved daytime alertness/consistency.
- The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety
PubMed ID: 8526970
AMPT increased sleepiness and L‑dopa reversed this — strong evidence that dopamine restoration improves alertness.
- Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD
PubMed ID: 11479392
Tolcapone adjunct produced functional gain and reduced L‑Dopa requirements—likely to improve daytime alertness and responsiveness.
- Dopamine and semantic activation: an investigation of masked direct and indirect priming
PubMed ID: 14751003
Levodopa shortened semantic priming windows, indicating shifts in temporal processing/alertness.
- Differential effects of subthalamic nucleus stimulation in advanced Parkinson disease on reaction time performance
PubMed ID: 16273395
DBS improved simple and complex reaction times → strong objective measure of improved alertness/processing speed.
- A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease
PubMed ID: 29278279
Camicinal sped levodopa Tmax and increased ON time, which could translate into better alertness during day.
- Dopamine and light: effects on facial emotion recognition
PubMed ID: 28633582
Faster reaction times and improved recognition after altered Phe/Tyr availability indicate dopaminergic contributions to alertness.
- Intellectual development in 12-year-old children treated for phenylketonuria
PubMed ID: 1985428
Developmental cognitive impairment from high Phe implies reduced alertness/function; Phe control associates with better alertness in PKU contexts.
- Effects of serotonin depletion and dopamine depletion on bimodal divided attention
PubMed ID: 30295116
APTD/tyrosine manipulations changed auditory reaction time (faster when DA precursors higher), supporting an alertness effect from Phe/Tyr availability.
- Neuropsychiatric Function Improvement in Pediatric Patients with Phenylketonuria
PubMed ID: 37263523
Lowering blood Phe with sapropterin improved attention/executive symptoms; alertness likely improved as part of cognitive gain.
- Brain glucose uptake is associated with endogenous glucose production in obese patients before and after bariatric surgery and predicts metabolic outcome at follow-up
PubMed ID: 30098134
Strong correlation between Phe levels and insulin-stimulated brain glucose uptake suggests Phe-related modulation of brain alertness/metabolism.
Focus & concentration (16)
- Intellectual development in 12-year-old children treated for phenylketonuria
PubMed ID: 1985428
Strong evidence that elevated developmental Phe harms cognitive functions relevant to focus/attention in PKU.
- Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients
PubMed ID: 21491106
PKU subjects had poorer Stroop performance (attention/executive) — Phe control relevant to focus.
- A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria
PubMed ID: 25533024
Sapropterin lowered Phe and produced clear improvement in inattentive ADHD symptoms in PKU patients (direct clinical evidence).
- Dopamine depletion effects on cognitive flexibility as modulated by tDCS of the dlPFC
PubMed ID: 31494070
APTD slowed RTs and altered cognitive flexibility — directly shows catecholamine-precursor effects on performance speed and control.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Precursor depletion decreased stimulant effects and mania — shows precursor availability strongly affects dopamine-mediated focus/arousal (inverse evidence).
- Bidirectional modulation of reward-guided decision making by dopamine
PubMed ID: 40439740
L‑DOPA increased weighting of reward magnitude/probability in choices, reflecting enhanced task‑relevant processing.
- L-DOPA and oxytocin influence the neural correlates of performance monitoring for self and others
PubMed ID: 38286857
L‑DOPA/oxytocin fMRI altered error‑monitoring circuitry, consistent with effects on attentional processes.
- Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
PubMed ID: 30366815
Lowering pathological Phe can improve attention-related neurofunction in PKU contexts.
- Neuropsychiatric Function Improvement in Pediatric Patients with Phenylketonuria
PubMed ID: 37263523
Randomized PKU trial: sapropterin lowered Phe and produced measurable improvements in attention/executive symptoms.
- Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial
PubMed ID: 39368841
Major blood‑Phe lowering in PKU (sepiapterin) — supports improved cognition/focus in Phe‑sensitive patients.
- The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety
PubMed ID: 8526970
Reversal of AMPT-induced sleepiness by L‑dopa implies catecholamines restore alert focus.
- Levodopa: faster and better word learning in normal humans
PubMed ID: 15236398
Levodopa improved learning speed and retention, consistent with improved sustained task focus during training.
- Differential effects of subthalamic nucleus stimulation in advanced Parkinson disease on reaction time performance
PubMed ID: 16273395
DBS improved reaction times → supports improved attentional/processing speed components of focus.
- The effects of combination levodopa-ropinirole on cognitive improvement and treatment outcome in individuals with cocaine use disorder: A bayesian mediation analysis
PubMed ID: 34102508
Levodopa regimens improved attention/impulsivity measures that mediated clinical benefit—indirect support via DA synthesis pathway.
- Dopamine and light: effects on facial emotion recognition
PubMed ID: 28633582
Altered reaction speed and face-recognition accuracy after Phe/Tyr depletion implies catecholamine‑dependent effects on focused processing.
- Effects of L-dopa during auditory instrumental learning in humans
PubMed ID: 23285070
Single‑dose L‑dopa raised auditory cortical activity during instrumental learning—direct evidence for focused sensory/cognitive modulation.
Sleep quality (9)
- Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa
PubMed ID: 38465885
Foslevodopa/foscarbidopa improvements in sleep scores correlated with QoL and reduced OFF time in advanced PD.
- Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial
PubMed ID: 22101745
Pramipexole and dual‑release levodopa improved RLS/PLM measures — supports dopaminergic influence on sleep‑related motor symptoms.
- L-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children
PubMed ID: 21463967
Levodopa improved RLS/PLMS in children — a clear, clinically relevant impact on sleep disturbances linked to dopamine.
- Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial
PubMed ID: 17274039
Levodopa improved RLS symptoms though less effective than cabergoline—relevant to sleep quality.
- Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial
PubMed ID: 10617168
Nightly levodopa produced rapid, significant reductions in PLMs and improved subjective/objective sleep quality in RLS—direct benefit to sleep continuity.
- A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms
PubMed ID: 9932945
SR levodopa at bedtime reduced limb movements and improved sleep quality in RLS—direct sleep‑wake rhythm benefit.
- The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety
PubMed ID: 8526970
AMPT caused sleepiness reversed by L‑dopa → supports dopamine role in wakefulness/sleep regulation.
- Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease
PubMed ID: 40736131
Foslevodopa phase‑3 trials improved sleep scores and quality of life alongside motor benefits.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Precursor depletion reduced stimulant (dopaminergic) effects; dopamine strongly influences arousal and sleep-wake state (inverse evidence).
Memory (9)
- Intellectual development in 12-year-old children treated for phenylketonuria
PubMed ID: 1985428
Clear association between higher developmental Phe and poorer cognitive/achievement scores, including aspects of memory.
- Pre-attentive processing in children with early and continuously-treated PKU. Effects of concurrent Phe level and lifetime dietary control
PubMed ID: 21541727
Associations between higher Phe and reduced MMN/VEP performance suggest impacts on early sensory processing that can affect memory encoding.
- Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
PubMed ID: 29653686
Long‑term pegvaliase program showed neuropsychiatric improvements in PKU; memory is among cognitive domains likely affected though not always isolated.
- Preliminary evidence for an association between intake of high-fat high-sugar diet, variations in peripheral dopamine precursor availability and dopamine-dependent cognition in humans
PubMed ID: 33270945
APTD reduced working‑memory (OSPAN) performance in one dietary subgroup—direct evidence linking Phe/Tyr availability to memory function (moderate‑strong).
- Levodopa: faster and better word learning in normal humans
PubMed ID: 15236398
Levodopa increased long‑term retention of newly learned words—direct evidence for improved memory.
- The efficacy of levodopa/carbidopa/entacapone on cognitive function in moderate to advanced Parkinson's disease and its relationship with peripheral inflammatory cytokines
PubMed ID: 40108546
Entacapone+levodopa increased MoCA scores (global cognition), suggesting potential memory benefits.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Phe/Tyr depletion lowered dopamine neurotransmission and reduced stimulant effects — inverse evidence that precursor availability influences memory-related dopaminergic functions.
- Dopamine depletion effects on cognitive flexibility as modulated by tDCS of the dlPFC
PubMed ID: 31494070
APTD slowed RTs and influenced cognitive flexibility; n-back working memory was measured, showing depletion effects.
- Brain glucose uptake is associated with endogenous glucose production in obese patients before and after bariatric surgery and predicts metabolic outcome at follow-up
PubMed ID: 30098134
Circulating Phe correlated with brain metabolic measures; such metabolic support can underlie memory performance.
Learning (7)
- Dopamine depletion effects on cognitive flexibility as modulated by tDCS of the dlPFC
PubMed ID: 31494070
APTD slowed RT and modulated cognitive flexibility — flexibility influences learning new tasks.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Removing Phe/Tyr reduced stimulant and mania effects and lowered dopamine neurotransmission — inverse evidence that precursor availability affects learning/arousal.
- L-DOPA improves extinction memory retrieval after successful fear extinction
PubMed ID: 31243481
Post‑extinction L‑DOPA enhanced extinction retrieval when extinction successful → context‑dependent facilitation of memory consolidation.
- Dopamine restores reward prediction errors in old age
PubMed ID: 23525044
L‑Dopa increased learning rate and restored reward‑prediction error signals in older adults—direct evidence for faster reinforcement learning.
- New approach to the rehabilitation of post-stroke focal cognitive syndrome: effect of levodopa combined with speech and language therapy on functional recovery from aphasia
PubMed ID: 19268976
Levodopa administered before speech therapy produced superior language learning gains—direct evidence for accelerated relearning.
- Levodopa: faster and better word learning in normal humans
PubMed ID: 15236398
Five days of levodopa clearly increased vocabulary learning speed and retention in healthy adults.
- Intellectual development in 12-year-old children treated for phenylketonuria
PubMed ID: 1985428
Strong observational evidence that elevated childhood Phe impairs learning and achievement in PKU.
Skin health (6)
- Relative Oral Bioavailability and Food Effects of Two Sepiapterin Formulations in Healthy Participants
PubMed ID: 38156759
BH4 is a cofactor required for conversion of phenylalanine to tyrosine and downstream melanin synthesis—PK evidence for BH4 exposure/bioavailability.
- Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria
PubMed ID: 31296884
Nitisinone caused large increases in serum tyrosine (the immediate melanin precursor), directly relevant to pigment biosynthesis potential.
- A double-blind vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of melasma in females
PubMed ID: 24910270
Topical undecylenoyl phenylalanine 2% (a Phe derivative) produced significant lightening of melasma—direct evidence relating a phenylalanine-based agent to pigment modulation.
- Reduction in the appearance of facial hyperpigmentation by topical N-undecyl-10-enoyl-L-phenylalanine and its combination with niacinamide
PubMed ID: 19958429
Topical N‑undecylenoyl‑L‑phenylalanine plus niacinamide reduced facial hyperpigmentation—direct clinical pigment effect.
- [Evaluation of an antioxidant and mitochondria-stimulating cream formula on the skin of patients with stable common vitiligo]
PubMed ID: 17432541
Direct: oral phenylalanine (with other therapies) increased skin repigmentation and melanocyte counts in vitiligo patients.
- Phenylalanine Butyramide: A Butyrate Derivative as a Novel Inhibitor of Tyrosinase
PubMed ID: 39000417
Topical phenylalanine‑butyramide (PBA) inhibited tyrosinase and produced measurable skin lightening and reduced pigmented spots in humans—direct pigment biology evidence (but effect is depigmenting).
Stress resilience (4)
- Effects of Dopaminergic Therapy with Levodopa (L-DOPA) on Fear and Anxiety-Related Circuits and Symptoms in Patients with Depression and Higher Inflammation
PubMed ID: 41478464
L‑DOPA increased amygdala–vmPFC connectivity and reduced anxiety/PTSD symptoms in higher‑inflammation patients.
- Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
PubMed ID: 11581118
Precursor depletion reduced dopamine effects and mania ratings — shows precursor availability influences stress/reactivity of catechol systems (inverse evidence).
- Blue Monday: Co-occurring Stimulant Use and HIV Persistence Predict Dysregulated Catecholamine Synthesis
PubMed ID: 33165125
Altered P/T ratio associated with stimulant use and depression risk, indicating Phe/Tyr metabolism may influence stress-related mood vulnerability.
- The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety
PubMed ID: 8526970
AMPT increased anxiety and L‑dopa reversed it → supports catecholamine role in reducing stress vulnerability.
Appetite suppression (3)
- Effects of L-phenylalanine on energy intake in overweight and obese women: interactions with dietary restraint status
PubMed ID: 18342398
Single-dose L-phenylalanine reduced intake (~11%) in a subgroup of less rigidly restrained women, though nausea confounded some effects.
- Serotonin and dopamine differentially affect appetitive and aversive general Pavlovian-to-instrumental transfer
PubMed ID: 25034118
Tyrosine/phenylalanine depletion specifically reduced appetitive Pavlovian‑to‑instrumental transfer → direct link to appetite/motivated eating.
- Dopamine Depletion Reduces Food-Related Reward Activity Independent of BMI
PubMed ID: 26450814
APTD blunted striatal reward responses to food items — directly relevant to neural mechanisms of appetite/desire for food.
Forms of Phenylalanine
The form a label may print instead of Phenylalanine. Each is a different substance with its own identifier, and none of them has research of its own — the studies are the ones on this page.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Phenylalanine
Search all1185 products whose verified label declares Phenylalanine — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.